Letter to the EditorCurrently, hepatitis C infection is present in 180 million people worldwide and is the main cause of end-stage liver disease and an indication for liver transplantation. 1 The different genotypes are independent of the clinical course of chronic hepatitis C but have a great impact on treatment response. New direct-acting antivirals yield a high rate of clinical response and cure. Sofosbuvir (SOF), a NS5B nucleotide inhibitor with pangenotypic activity, presents a high genetic barrier. Simeprevir (SIM), a secondgeneration NS3/A4 protease inhibitor, has activity against genotypes 1, 2, 4, 5, and 6. Also, it shows an interesting characteristic: its resistance-associated variants often disappear gradually once the treatment is stopped. 2 Currently, data on viral response in approved and experimental treatments in HCV genotype 5 (HCV-5) are scarce. Therefore, we propose to describe the first case of healing in a HCV-5 treatment-naïve cirrhotic patient treated with SIM, SOF, and ribavirin (SIM/SOF/RBV)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.